Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech
Identifieur interne : 002886 ( Main/Corpus ); précédent : 002885; suivant : 002887Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech
Auteurs : Serge Pinto ; Michèle Gentil ; Paul Krack ; Paul Sauleau ; Valérie Fraix ; Alim-Louis Benabid ; Pierre PollakSource :
- Movement Disorders [ 0885-3185 ] ; 2005-11.
English descriptors
Abstract
Levodopa (L‐dopa) and subthalamic nucleus (STN) stimulation treatments have been associated with both improvement and exacerbation of dysarthria in Parkinson's disease (PD). We report four cases illustrating variant responses of dysarthria to dopaminergic and STN stimulation therapies. Patients' motor disability and dysarthria were perceptually rated by the Unified Parkinson's Disease Rating Scale (UPDRS) in four conditions according to medication and STN stimulation. Dedicated software packages allowed acquisition and analysis of acoustic recordings. Case 1, who had a severe off period aphonia, experienced improvement of speech induced by both levodopa and STN stimulation. In Case 2, both treatments worsened speech due to the appearance of dyskinesias. Case 3 had a dysarthria exacerbation induced by STN stimulation with parameters above optimal levels, interpreted as current diffusion from the STN to corticobulbar fibers. In Case 4, dysarthria exacerbation occurred with stimulation at an electrode contact located caudally to the target, also arguing for current diffusion as a potential mechanism of speech worsening. The presented cases demonstrated variant effects in relation to L‐dopa and STN stimulation on speech. It seems that motor speech subcomponents can be improved like other limb motor aspect, but that complex coordination of all speech anatomical substrates is not responsive to STN stimulation. These hypotheses may be helpful for better understanding and management of STN stimulation effects on motor speech and skeleton–motor subsystems. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20601
Links to Exploration step
ISTEX:077060E6701AD06B35201829319A89FB791126D1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech</title><author><name sortKey="Pinto, Serge" sort="Pinto, Serge" uniqKey="Pinto S" first="Serge" last="Pinto">Serge Pinto</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Gentil, Michele" sort="Gentil, Michele" uniqKey="Gentil M" first="Michèle" last="Gentil">Michèle Gentil</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Krack, Paul" sort="Krack, Paul" uniqKey="Krack P" first="Paul" last="Krack">Paul Krack</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Sauleau, Paul" sort="Sauleau, Paul" uniqKey="Sauleau P" first="Paul" last="Sauleau">Paul Sauleau</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Service des Explorations Fonctionnelles Neurologiques, Rennes University Hospital, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Fraix, Valerie" sort="Fraix, Valerie" uniqKey="Fraix V" first="Valérie" last="Fraix">Valérie Fraix</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Benabid, Alim Ouis" sort="Benabid, Alim Ouis" uniqKey="Benabid A" first="Alim-Louis" last="Benabid">Alim-Louis Benabid</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département de Neurochirurgie, Grenoble University Hospital, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:077060E6701AD06B35201829319A89FB791126D1</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20601</idno><idno type="url">https://api.istex.fr/document/077060E6701AD06B35201829319A89FB791126D1/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002886</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech</title><author><name sortKey="Pinto, Serge" sort="Pinto, Serge" uniqKey="Pinto S" first="Serge" last="Pinto">Serge Pinto</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Gentil, Michele" sort="Gentil, Michele" uniqKey="Gentil M" first="Michèle" last="Gentil">Michèle Gentil</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Krack, Paul" sort="Krack, Paul" uniqKey="Krack P" first="Paul" last="Krack">Paul Krack</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Sauleau, Paul" sort="Sauleau, Paul" uniqKey="Sauleau P" first="Paul" last="Sauleau">Paul Sauleau</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Service des Explorations Fonctionnelles Neurologiques, Rennes University Hospital, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Fraix, Valerie" sort="Fraix, Valerie" uniqKey="Fraix V" first="Valérie" last="Fraix">Valérie Fraix</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Benabid, Alim Ouis" sort="Benabid, Alim Ouis" uniqKey="Benabid A" first="Alim-Louis" last="Benabid">Alim-Louis Benabid</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département de Neurochirurgie, Grenoble University Hospital, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name><affiliation><mods:affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-11">2005-11</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1507">1507</biblScope><biblScope unit="page" to="1515">1515</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">077060E6701AD06B35201829319A89FB791126D1</idno><idno type="DOI">10.1002/mds.20601</idno><idno type="ArticleID">MDS20601</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term><term>Parkinson's disease</term><term>dysarthria</term><term>speech</term><term>subthalamic nucleus stimulation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa (L‐dopa) and subthalamic nucleus (STN) stimulation treatments have been associated with both improvement and exacerbation of dysarthria in Parkinson's disease (PD). We report four cases illustrating variant responses of dysarthria to dopaminergic and STN stimulation therapies. Patients' motor disability and dysarthria were perceptually rated by the Unified Parkinson's Disease Rating Scale (UPDRS) in four conditions according to medication and STN stimulation. Dedicated software packages allowed acquisition and analysis of acoustic recordings. Case 1, who had a severe off period aphonia, experienced improvement of speech induced by both levodopa and STN stimulation. In Case 2, both treatments worsened speech due to the appearance of dyskinesias. Case 3 had a dysarthria exacerbation induced by STN stimulation with parameters above optimal levels, interpreted as current diffusion from the STN to corticobulbar fibers. In Case 4, dysarthria exacerbation occurred with stimulation at an electrode contact located caudally to the target, also arguing for current diffusion as a potential mechanism of speech worsening. The presented cases demonstrated variant effects in relation to L‐dopa and STN stimulation on speech. It seems that motor speech subcomponents can be improved like other limb motor aspect, but that complex coordination of all speech anatomical substrates is not responsive to STN stimulation. These hypotheses may be helpful for better understanding and management of STN stimulation effects on motor speech and skeleton–motor subsystems. © 2005 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Serge Pinto PhD</name><affiliations><json:string>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</json:string><json:string>Current Address: Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Michèle Gentil PhD</name><affiliations><json:string>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</json:string></affiliations></json:item><json:item><name>Paul Krack MD</name><affiliations><json:string>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</json:string><json:string>Département de Neurologie, Grenoble University Hospital, Grenoble, France</json:string></affiliations></json:item><json:item><name>Paul Sauleau MD</name><affiliations><json:string>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</json:string><json:string>Service des Explorations Fonctionnelles Neurologiques, Rennes University Hospital, Rennes, France</json:string></affiliations></json:item><json:item><name>Valérie Fraix MD</name><affiliations><json:string>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</json:string><json:string>Département de Neurologie, Grenoble University Hospital, Grenoble, France</json:string></affiliations></json:item><json:item><name>Alim‐Louis Benabid MD, PhD</name><affiliations><json:string>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</json:string><json:string>Département de Neurochirurgie, Grenoble University Hospital, Grenoble, France</json:string></affiliations></json:item><json:item><name>Pierre Pollak MD</name><affiliations><json:string>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</json:string><json:string>Département de Neurologie, Grenoble University Hospital, Grenoble, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dysarthria</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>speech</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>L‐dopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>subthalamic nucleus stimulation</value></json:item></subject><articleId><json:string>MDS20601</json:string></articleId><language><json:string>eng</json:string></language><abstract>Levodopa (L‐dopa) and subthalamic nucleus (STN) stimulation treatments have been associated with both improvement and exacerbation of dysarthria in Parkinson's disease (PD). We report four cases illustrating variant responses of dysarthria to dopaminergic and STN stimulation therapies. Patients' motor disability and dysarthria were perceptually rated by the Unified Parkinson's Disease Rating Scale (UPDRS) in four conditions according to medication and STN stimulation. Dedicated software packages allowed acquisition and analysis of acoustic recordings. Case 1, who had a severe off period aphonia, experienced improvement of speech induced by both levodopa and STN stimulation. In Case 2, both treatments worsened speech due to the appearance of dyskinesias. Case 3 had a dysarthria exacerbation induced by STN stimulation with parameters above optimal levels, interpreted as current diffusion from the STN to corticobulbar fibers. In Case 4, dysarthria exacerbation occurred with stimulation at an electrode contact located caudally to the target, also arguing for current diffusion as a potential mechanism of speech worsening. The presented cases demonstrated variant effects in relation to L‐dopa and STN stimulation on speech. It seems that motor speech subcomponents can be improved like other limb motor aspect, but that complex coordination of all speech anatomical substrates is not responsive to STN stimulation. These hypotheses may be helpful for better understanding and management of STN stimulation effects on motor speech and skeleton–motor subsystems. © 2005 Movement Disorder Society</abstract><qualityIndicators><score>7.736</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1606</abstractCharCount><pdfWordCount>6031</pdfWordCount><pdfCharCount>39957</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>228</abstractWordCount></qualityIndicators><title>Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech</title><genre><json:string>article</json:string></genre><host><volume>20</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>1515</last><first>1507</first></pages><issn><json:string>0885-3185</json:string></issn><issue>11</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/mds.20601</json:string></doi><id>077060E6701AD06B35201829319A89FB791126D1</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/077060E6701AD06B35201829319A89FB791126D1/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/077060E6701AD06B35201829319A89FB791126D1/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/077060E6701AD06B35201829319A89FB791126D1/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2005</date></publicationStmt><notesStmt><note>Institut National de la Santé et de la Recherche Médicale (France)</note><note>Fédération Française des Groupements de Parkinsoniens (France)</note><note>Fondation Simone et Cino Del Duca (France)</note><note>Ministère de la Recherche (France)</note><note>Wellcome Trust (U.K.)</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech</title><author><persName><forename type="first">Serge</forename><surname>Pinto</surname></persName><roleName type="degree">PhD</roleName><note type="correspondence"><p>Correspondence: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, 8/11 Queen Square, London WC1N 3BG, United Kingdom</p></note><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Current Address: Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</affiliation></author><author><persName><forename type="first">Michèle</forename><surname>Gentil</surname></persName><roleName type="degree">PhD</roleName><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation></author><author><persName><forename type="first">Paul</forename><surname>Krack</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</affiliation></author><author><persName><forename type="first">Paul</forename><surname>Sauleau</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Service des Explorations Fonctionnelles Neurologiques, Rennes University Hospital, Rennes, France</affiliation></author><author><persName><forename type="first">Valérie</forename><surname>Fraix</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</affiliation></author><author><persName><forename type="first">Alim‐Louis</forename><surname>Benabid</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Département de Neurochirurgie, Grenoble University Hospital, Grenoble, France</affiliation></author><author><persName><forename type="first">Pierre</forename><surname>Pollak</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-11"></date><biblScope unit="volume">20</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1507">1507</biblScope><biblScope unit="page" to="1515">1515</biblScope></imprint></monogr><idno type="istex">077060E6701AD06B35201829319A89FB791126D1</idno><idno type="DOI">10.1002/mds.20601</idno><idno type="ArticleID">MDS20601</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Levodopa (L‐dopa) and subthalamic nucleus (STN) stimulation treatments have been associated with both improvement and exacerbation of dysarthria in Parkinson's disease (PD). We report four cases illustrating variant responses of dysarthria to dopaminergic and STN stimulation therapies. Patients' motor disability and dysarthria were perceptually rated by the Unified Parkinson's Disease Rating Scale (UPDRS) in four conditions according to medication and STN stimulation. Dedicated software packages allowed acquisition and analysis of acoustic recordings. Case 1, who had a severe off period aphonia, experienced improvement of speech induced by both levodopa and STN stimulation. In Case 2, both treatments worsened speech due to the appearance of dyskinesias. Case 3 had a dysarthria exacerbation induced by STN stimulation with parameters above optimal levels, interpreted as current diffusion from the STN to corticobulbar fibers. In Case 4, dysarthria exacerbation occurred with stimulation at an electrode contact located caudally to the target, also arguing for current diffusion as a potential mechanism of speech worsening. The presented cases demonstrated variant effects in relation to L‐dopa and STN stimulation on speech. It seems that motor speech subcomponents can be improved like other limb motor aspect, but that complex coordination of all speech anatomical substrates is not responsive to STN stimulation. These hypotheses may be helpful for better understanding and management of STN stimulation effects on motor speech and skeleton–motor subsystems. © 2005 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>dysarthria</term></item><item><term>speech</term></item><item><term>L‐dopa</term></item><item><term>subthalamic nucleus stimulation</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-11-24">Received</change><change when="2005-02-17">Registration</change><change when="2005-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/077060E6701AD06B35201829319A89FB791126D1/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/mds.v20:11</doi><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">11</numbering></numberingGroup><coverDate startDate="2005-11">November 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="180" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20601</doi><idGroup><id type="unit" value="MDS20601"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2005 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-11-24"></event><event type="manuscriptRevised" date="2005-02-11"></event><event type="manuscriptAccepted" date="2005-02-17"></event><event type="publishedOnlineEarlyUnpaginated" date="2005-07-21"></event><event type="firstOnline" date="2005-07-21"></event><event type="publishedOnlineFinalForm" date="2005-10-27"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1507</numbering><numbering type="pageLast">1515</numbering></numberingGroup><correspondenceTo>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, 8/11 Queen Square, London WC1N 3BG, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20601.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="62"></count><count type="wordTotal" number="5803"></count></countGroup><titleGroup><title type="main" xml:lang="en">Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech</title><title type="short" xml:lang="en"><sc>L</sc>‐Dopa and STN Stimulation Effects on Speech</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" currentRef="#curr1" corresponding="yes"><personName><givenNames>Serge</givenNames><familyName>Pinto</familyName><degrees>PhD</degrees></personName><contactDetails><email>s.pinto@ion.ucl.ac.uk</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Michèle</givenNames><familyName>Gentil</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Paul</givenNames><familyName>Krack</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af3"><personName><givenNames>Paul</givenNames><familyName>Sauleau</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Valérie</givenNames><familyName>Fraix</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1 #af4"><personName><givenNames>Alim‐Louis</givenNames><familyName>Benabid</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Pierre</givenNames><familyName>Pollak</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Service des Explorations Fonctionnelles Neurologiques, Rennes University Hospital, Rennes, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="FR" type="organization"><unparsedAffiliation>Département de Neurochirurgie, Grenoble University Hospital, Grenoble, France</unparsedAffiliation></affiliation><affiliation xml:id="curr1" countryCode="GB"><unparsedAffiliation>Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">dysarthria</keyword><keyword xml:id="kwd3">speech</keyword><keyword xml:id="kwd4"><sc>L</sc>‐dopa</keyword><keyword xml:id="kwd5">subthalamic nucleus stimulation</keyword></keywordGroup><fundingInfo><fundingAgency>Institut National de la Santé et de la Recherche Médicale (France)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Fédération Française des Groupements de Parkinsoniens (France)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Fondation Simone et Cino Del Duca (France)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Ministère de la Recherche (France)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Wellcome Trust (U.K.)</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Levodopa (<sc>L</sc>‐dopa) and subthalamic nucleus (STN) stimulation treatments have been associated with both improvement and exacerbation of dysarthria in Parkinson's disease (PD). We report four cases illustrating variant responses of dysarthria to dopaminergic and STN stimulation therapies. Patients' motor disability and dysarthria were perceptually rated by the Unified Parkinson's Disease Rating Scale (UPDRS) in four conditions according to medication and STN stimulation. Dedicated software packages allowed acquisition and analysis of acoustic recordings. Case 1, who had a severe <i>off</i> period aphonia, experienced improvement of speech induced by both levodopa and STN stimulation. In Case 2, both treatments worsened speech due to the appearance of dyskinesias. Case 3 had a dysarthria exacerbation induced by STN stimulation with parameters above optimal levels, interpreted as current diffusion from the STN to corticobulbar fibers. In Case 4, dysarthria exacerbation occurred with stimulation at an electrode contact located caudally to the target, also arguing for current diffusion as a potential mechanism of speech worsening. The presented cases demonstrated variant effects in relation to <sc>L</sc>‐dopa and STN stimulation on speech. It seems that motor speech subcomponents can be improved like other limb motor aspect, but that complex coordination of all speech anatomical substrates is not responsive to STN stimulation. These hypotheses may be helpful for better understanding and management of STN stimulation effects on motor speech and skeleton–motor subsystems. © 2005 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>L‐Dopa and STN Stimulation Effects on Speech</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech</title></titleInfo><name type="personal"><namePart type="given">Serge</namePart><namePart type="family">Pinto</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Current Address: Institute of Neurology, Sobell Department of Motor Neuroscience and Movement Disorders, London, United Kingdom</affiliation><description>Correspondence: Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, 8/11 Queen Square, London WC1N 3BG, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michèle</namePart><namePart type="family">Gentil</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul</namePart><namePart type="family">Krack</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul</namePart><namePart type="family">Sauleau</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Service des Explorations Fonctionnelles Neurologiques, Rennes University Hospital, Rennes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Valérie</namePart><namePart type="family">Fraix</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alim‐Louis</namePart><namePart type="family">Benabid</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Département de Neurochirurgie, Grenoble University Hospital, Grenoble, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Pollak</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurosciences Précliniques, INSERM Unité 318, Grenoble, France</affiliation><affiliation>Département de Neurologie, Grenoble University Hospital, Grenoble, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-11</dateIssued><dateCaptured encoding="w3cdtf">2004-11-24</dateCaptured><dateValid encoding="w3cdtf">2005-02-17</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">2</extent><extent unit="references">62</extent><extent unit="words">5803</extent></physicalDescription><abstract lang="en">Levodopa (L‐dopa) and subthalamic nucleus (STN) stimulation treatments have been associated with both improvement and exacerbation of dysarthria in Parkinson's disease (PD). We report four cases illustrating variant responses of dysarthria to dopaminergic and STN stimulation therapies. Patients' motor disability and dysarthria were perceptually rated by the Unified Parkinson's Disease Rating Scale (UPDRS) in four conditions according to medication and STN stimulation. Dedicated software packages allowed acquisition and analysis of acoustic recordings. Case 1, who had a severe off period aphonia, experienced improvement of speech induced by both levodopa and STN stimulation. In Case 2, both treatments worsened speech due to the appearance of dyskinesias. Case 3 had a dysarthria exacerbation induced by STN stimulation with parameters above optimal levels, interpreted as current diffusion from the STN to corticobulbar fibers. In Case 4, dysarthria exacerbation occurred with stimulation at an electrode contact located caudally to the target, also arguing for current diffusion as a potential mechanism of speech worsening. The presented cases demonstrated variant effects in relation to L‐dopa and STN stimulation on speech. It seems that motor speech subcomponents can be improved like other limb motor aspect, but that complex coordination of all speech anatomical substrates is not responsive to STN stimulation. These hypotheses may be helpful for better understanding and management of STN stimulation effects on motor speech and skeleton–motor subsystems. © 2005 Movement Disorder Society</abstract><note type="funding">Institut National de la Santé et de la Recherche Médicale (France)</note><note type="funding">Fédération Française des Groupements de Parkinsoniens (France)</note><note type="funding">Fondation Simone et Cino Del Duca (France)</note><note type="funding">Ministère de la Recherche (France)</note><note type="funding">Wellcome Trust (U.K.)</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>dysarthria</topic><topic>speech</topic><topic>L‐dopa</topic><topic>subthalamic nucleus stimulation</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>11</number></detail><extent unit="pages"><start>1507</start><end>1515</end><total>8</total></extent></part></relatedItem><identifier type="istex">077060E6701AD06B35201829319A89FB791126D1</identifier><identifier type="DOI">10.1002/mds.20601</identifier><identifier type="ArticleID">MDS20601</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002886 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002886 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:077060E6701AD06B35201829319A89FB791126D1
|texte= Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech
}}
| This area was generated with Dilib version V0.6.23. |  |